Solara Pharma is consolidating after a 25% monthly rally, trading near a key resistance zone. SEBI-registered analyst Vijay Gupta sees a healthy setup, with bullish technicals like CCI at 98 and Ichimoku support. Q4 profits tripled, margins improved, and debt fell. With upbeat FY26 guidance and stronger exports, a breakout above current levels could mark the next leg higher.